OncoMatch/Clinical Trials/NCT07360314
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Is NCT07360314 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including M7437 and M7437 for advanced solid tumors.
Treatment: M7437 · M7437 — The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expression, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), epithelial ovarian carcinoma (EOC), squamous cell carcinoma of the head and neck (SCCHN), pancreatic ductal adenocarcinoma (PDAC), and gastric cancer (GC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Required: LY6E prevalent and high expression (prevalent and high)
known prevalent and high Ly6E expression
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapies
Participants should have an unresectable locally advanced or metastatic solid tumor that is refractory to standard therapies, or have no standard therapies, or for which no standard therapy is judged appropriate by the Investigator.
Lab requirements
Blood counts
within safe levels
Kidney function
within safe levels
Liver function
within safe levels
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Yale University - Yale University School of Medicine · New Haven, Connecticut
- Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center · Huntersville, North Carolina
- NEXT Houston · Galveston, Texas
- NEXT Oncology - PARENT · San Antonio, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify